Isoaspartyl post-translational modification triggers anti-tumor T and B lymphocyte immunity.
about
Immunogenicity of Biotherapeutics: Causes and Association with Posttranslational ModificationsTumor neoantigens: building a framework for personalized cancer immunotherapyAbnormal isoaspartyl residues in erythrocyte membranes from psoriatic patients.Non-repair pathways for minimizing protein isoaspartyl damage in the yeast Saccharomyces cerevisiae.Autoimmunity to isomerized histone H2B in systemic lupus erythematosus.Autoantigens in systemic autoimmunity: critical partner in pathogenesisBeta-cell mass and type 1 diabetes: going, going, gone?Isoaspartic acid is present at specific sites in myelin basic protein from multiple sclerosis patients: could this represent a trigger for disease onset?Polyclonal immune responses to antigens associated with cancer signaling pathways and new strategies to enhance cancer vaccinesTransmethylation in immunity and autoimmunity.Stability of IgG isotypes in serum.Quality attributes of recombinant therapeutic proteins: an assessment of impact on safety and efficacy as part of a quality by design development approach.Minimizing immunogenicity of biopharmaceuticals by controlling critical quality attributes of proteins.Isoaspartylation appears to trigger small cell lung cancer-associated autoimmunity against neuronal protein ELAVL4.Comparison of the in vitro and in vivo stability of a succinimide intermediate observed on a therapeutic IgG1 molecule.Molecular characterisation and expression analysis of SEREX-defined antigen NUCB2 in gastric epithelium, gastritis and gastric cancer.Can the Fact That Myelin Proteins Are Old and Break down Explain the Origin of Multiple Sclerosis in Some People?
P2860
Q26738810-32DE5B70-8829-443B-9F50-26D492461F7EQ28082704-53F4D05E-72D0-44CC-A661-5048EA91D261Q30417395-237C5250-E282-4364-A7AC-789B095C7668Q33761245-3CEAA0FF-E014-4A74-938C-E6890F65DA53Q36527598-15A81487-5866-4A3A-B0B4-528B03E80A07Q36880045-B5BBC596-04D8-4E09-B1C5-1EEACA9C22F7Q36943672-9D1835D8-1AD6-4BA6-B183-B7F7DA47A17CQ37171483-36762479-47F7-4018-AC37-00F51082DAB9Q37173925-330111D6-7FF7-4E12-A9B9-DB806DECA04EQ37191628-523CC5E8-7565-4056-988B-F1A1E6456796Q37734089-86D9D217-F2CD-4748-95AA-098F01E96912Q37999739-53FE01F1-2720-45DB-AB2C-765B2E80AF44Q38048706-D23B9D96-BC84-46FB-9A5B-C6E430D0795FQ39304645-FD01DBB5-C7CB-4474-A62C-8F951AA65546Q41913558-43CFCC4C-18B4-4CF4-8D89-6251771E1510Q46467709-7978C68F-68E2-4C69-A817-35DF99C1D6CEQ58739031-EBD4AFE3-6F3B-411A-AEB3-6B098533FD37
P2860
Isoaspartyl post-translational modification triggers anti-tumor T and B lymphocyte immunity.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
2006年论文
@zh
2006年论文
@zh-cn
name
Isoaspartyl post-translational ...... r T and B lymphocyte immunity.
@en
type
label
Isoaspartyl post-translational ...... r T and B lymphocyte immunity.
@en
prefLabel
Isoaspartyl post-translational ...... r T and B lymphocyte immunity.
@en
P2093
P2860
P356
P1476
Isoaspartyl post-translational ...... or T and B lymphocyte immunity
@en
P2093
Bohdan P Harvey
Hester A Doyle
Mark J Mamula
Raymond A Koski
Renelle J Gee
Robert M Roman
P2860
P304
32676-32683
P356
10.1074/JBC.M604847200
P407
P50
P577
2006-09-01T00:00:00Z